Heterotaxy Syndrome and Intestinal Rotation Abnormalities - A Prospective Study

This study is currently recruiting participants.
Verified March 2013 by University of Alberta
Sponsor:
Information provided by (Responsible Party):
Lindsay Ryerson, University of Alberta
ClinicalTrials.gov Identifier:
NCT01591928
First received: May 2, 2012
Last updated: March 22, 2013
Last verified: March 2013

May 2, 2012
March 22, 2013
March 2012
March 2017   (final data collection date for primary outcome measure)
Risk of midgut volvulus [ Designated as safety issue: Yes ]
Same as current
Complete list of historical versions of study NCT01591928 on ClinicalTrials.gov Archive Site
  • Morbidity secondary to a prophylactic Ladd procedure [ Designated as safety issue: Yes ]
  • Mortality secondary to a prophylactic Ladd procedure [ Designated as safety issue: Yes ]
Morbidity and mortality secondary to a prophylactic Ladd procedure [ Designated as safety issue: Yes ]
Not Provided
Not Provided
 
Heterotaxy Syndrome and Intestinal Rotation Abnormalities - A Prospective Study
Heterotaxy Syndrome and Intestinal Rotation Abnormalities - A Prospective Study

Infants with heterotaxy syndrome (HS) are born with an abnormal arrangement of organs along the right-left body axis. Abnormalities of intestinal rotation and fixation are commonly associated with HS. Malrotation is the most worrisome intestinal rotation abnormality (IRA). Advances in cardiac surgery have improved HS mortality such that there is increasing attention to IRA and their management. The objective of this research project is to prospectively observe a cohort of infants with HS and IRA and evaluate their long term outcomes. Specifically, the investigators would like to determine what is the natural history of asymptomatic IRA in patients with HS and what is the morbidity and mortality secondary to an elective Ladd procedure for asymptomatic IRA in a population with HS? The investigators plan a prospective, multi-center, observational study to follow this complicated group of patients. This will be a web-based database collected from major cardiac tertiary care centers in both Canada and the United States. Patients with HS will be recruited by their primary site and clinical data will be collected by their primary site prospectively throughout childhood until they are at least five years of age. This patient population will be followed by their own clinical care givers; this is not an interventional study. No additional clinic visits will be required and the patients will not have to be contacted. Patient medical records will be accessed by a member of the study team at the primary site at least once per year or more frequently if interventions are required or complications develop.

Not Provided
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample

All infants with heteterotaxy syndrome whose families provide written informed consent.

Heterotaxy Syndrome
Not Provided
Infants with heterotaxy syndrome
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
50
Not Provided
March 2017   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • All infants less than or equal to six months of age with a new diagnosis of heterotaxy syndrome

Exclusion Criteria:

Both
up to 6 Months
No
Contact: Lindsay Ryerson, MD 780 407 3396 ryerson@ualberta.ca
Canada
 
NCT01591928
2012-LR-01
No
Lindsay Ryerson, University of Alberta
University of Alberta
Not Provided
Principal Investigator: Lindsay Ryerson, MD University of Alberta
University of Alberta
March 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP